FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

vasimigton	, D.O. 20040	

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average bu	ırden									

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SIMARD JOHN					2. Issuer Name <b>and</b> Ticker or Trading Symbol XBiotech Inc. [XBIT]							(Che	elationship of ck all applica Director	able)	p Perso	( )			
(Last) (First) (Middle) 8201 E RIVERSIDE DRIVE					3. Date of Earliest Transaction (Month/Day/Year) 03/17/2016								Officer ( below)	give title		Other (s <sub>i</sub> below)	pecify		
BLDG. 4, STE 100					If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable						
(Street) AUSTIN TX 78744  (City) (State) (Zip)												Line)	X Form filed by One Reporting Person Form filed by More than One Reporting Person						
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date				. Transactio Date Month/Day/			2A. Deemed Execution Date, if any (Month/Day/Year		e, Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3,			Beneficia Owned Fo	rities eficially ed Following		Direct III Indirect Estr. 4)	7. Nature of Indirect Beneficial Ownership	
								[	Code	,	Amount	(	A) or D)	Price	Reported Transacti (Instr. 3 a	on(s)		1	Instr. 4)
Common Shares <sup>(1)</sup> 03/17				03/17/20	7/2016			0		500,0	00	D \$10		6,153,267			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		Derivative		Exp	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exe	e ercisable	Ex Da	piration te	Title	or No	nount ımber Shares	oer (Instr. 4)				
Option to sell <sup>(2)</sup>	\$10	03/17/2016		0			500,000	03/2	20/2014	03/	/20/2016	Comm		00,000	\$10	0		D	

## Explanation of Responses:

- 1. On March 17, 2016, Thorpe McKenzie exercised his option to purchase 500,000 shares of the Reporting Person's common stock at a purchase price of \$10 per share.
- 2. On March 20, 2014, the Reporting Person sold to Thorpe McKenzie an option to purchase 500,000 shares of his common stock at a purchase price of \$10 per share, which option is exercisable for a period of two years from the grant date.

<u>/s/ John Simard</u> 03/22/2016

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.